Acorda Therapeutics Soars Over 280% On Multiple Sclerosis Results
Shares of Acorda Therapeutics (ACOR) gained more than 280% at end of regular hours trading, and is up more than 5% in the after-hours session, as the company announced earlier in the day that its phase 3 MS clinical trial met primary endpoint.
The 3 months average daily volume is almost 30,000 shares a day, while today's action saw almost 25 million shares trade hands!
_
Shares of Acorda Therapeutics (ACOR) gained more than 280% at end of regular hours trading, and is up more than 5% in the after-hours session, as the company announced earlier in the day that its phase 3 MS clinical trial met primary endpoint.
The 3 months average daily volume is almost 30,000 shares a day, while today's action saw almost 25 million shares trade hands!
_
posted by Nico at
6:30 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home